Collect whole blood in a purple top (EDTA) tube.
Refrigerate sample until shipment. Send the sample at room temperature with overnight delivery for receipt Monday through Friday within 24 hours of collection.
Whole blood can be refrigerated until shipment.
Heparinized specimens, severely hemolyzed specimens, frozen, clotted or possibly commingled specimens, blood in non-sterile or leaky containers, mislabeled or inappropriately labeled specimens.
Do not heat, freeze or centrifuge blood before shipment. Refrigerate sample until shipment.
Mon - Fri 9:00am to 4:00pm
The primary clinical signs of BPES are blepharophimosis, ptosis and epicanthus inversus, although a variety of ocular and non-ocular features have been described. The association with amenorrhoea, infertility, and elevated gonadotropin levels in females has been noted. Based on the phenotype, two different types of BPES have been described. In BPES type I, eyelid malformations are associated with premature ovarian failure (POF), whereas in BPES type II, only the eyelid defect is observed. Mutations in the FOXL2 gene, a putative forkhead transcription factor gene, have been shown to cause both types of BPES.
The FOXL2 gene is located on chromosome 3q23. The inheritance pattern is autosomal dominant. Intragenic point mutations have been found in about 70% of BPES patients. They include premature stop codons, missense mutations, expansions of the region encoding the poly alanine domain and frameshift mutations leading to a shorter or longer protein. Thirty three percent of the point mutations detected in the coding region result in an expansion of the poly alanine tract of FOXL1, and are mainly responsible for BPES type II. Genomic rearrangements have been found in 16% of patients, including microdeletions encompassing FOXL2 (10%), translocations and deletions involving long-range non-genic conserved sequences far upstream and downstream of FOXL2 (6%). There is considerable intra- and interfamilial phenotypic variability with these mutations (ie., both BPES types can be caused by the same mutation).
We offer DNA sequence analysis and deletion/duplication testing of the entire coding region of the FOXL2 gene. These tests can be ordered as a panel or individually. PCR amplification and sequence analysis is performed on the coding exon including splice junctions. The patient’s gene sequence is compared to a reference sequence.
Sequence variants are classified as mutations, variants of unknown significance or benign
variants unrelated to disease. Variants of unknown significance may warrant further studies in the patient and other family members. Mutations in promoters, deep intronic regions and other regulatory regions will not be identified with this assay.
Point mutations in the FOXL2 gene are detected in 70% of cases with BPES.The analytical sensitivity for sequencing is close to 100%.
Deletion testing of the FOXL2 gene.
Known mutation analysis is available to family members for mutations previously identified by sequence analysis.
Test results with interpretation will be mailed and/or faxed to the referring physician or send out lab following completion of the test. Additional reports will be provided as requested.
The clinical utility of the assay is in confirming the clinical diagnosis of BPES in these patients, assessing the risk to other first degree relatives and genotyping at risk family members.
Whole blood in EDTA purple top tubes is the preferred sample. High molecular weight genomic DNA, cheek epithelial cells, or other samples containing DNA may be acceptable. Contact the laboratory for specific instructions regarding such samples before sending the sample.